ASH18: Legend's CAR-T brought back to reality

Legend Biotech was a barely known Chinese drugmaker until last summer, when it shot to stardom on early data that showed its CAR-T therapy was achieving a perfect overall response rate and few cases of serious side effects in a small group of multiple myeloma patients. The outcomes were impressive — and for some, too much so.